Kancera AB (publ) provides an update on the development of the company's pharmaceutical project and nominates a new drug candidate. Kancera's drug candidate KAND567 is developed primarily to reduce tissue damage in connection with myocardial infarction and as a treatment for COVID-19. The ongoing Phase IIa study in COVID- 19 has now dosed two thirds of the total of 40 patients. The third wave of the COVID-19 pandemic means that the hospitals involved in the study must prioritize life-saving treatment, which affects the available resources for clinical trials. The company still estimates that the study's four hospitals have the capacity to recruit all patients that remain during the current quarter, which means a certain delay compared to the previously communicated schedule (April).